false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Using Teriparatide: Combination and Sequential The ...
Using Teriparatide: Combination and Sequential The ...
Using Teriparatide: Combination and Sequential Therapies
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The webinar, led by Amal Shibli Rahal, an endocrinologist at the University of Iowa, focused on the intricacies of using teriparatide, an osteoanabolic agent, in combination or sequence with anti-resorptive agents like bisphosphonates and denosumab, in osteoporosis treatment. Teriparatide's use has been more liberal following the lifting of the black box warning regarding osteosarcoma.<br /><br />Key objectives included understanding the coupling between bone formation and resorption, and analyzing bone density responses in various drug sequence scenarios. One major point was that while teriparatide combined with a bisphosphonate doesn’t show significant benefit over teriparatide alone, layering a bisphosphonate after teriparatide may reopen the anabolic window, potentially enhancing bone density gains. The switch from bisphosphonates to teriparatide shows some efficacy but with reduced response compared to treatment-naive patients, and might initially cause slight bone density losses at the hip.<br /><br />For denosumab, using it in combination with teriparatide appears effective, demonstrating significant bone density improvements. However, directly switching from denosumab to teriparatide might cause a temporary dip in bone density, particularly at the hip.<br /><br />Post-teriparatide, transitioning to an anti-resorptive agent is crucial to maintain bone density gains. Switching from teriparatide to agents like romosuzumab shows promise, though the opposite sequence seems less effective.<br /><br />Audience inquiries covered topics such as long-term treatment strategies, risk evaluation, and the practicality of drug holidays. Dr. Shibli Rahal emphasized patient-specific approaches and that osteoporosis requires continuous management akin to chronic conditions.
Keywords
osteoporosis
teriparatide
bisphosphonates
denosumab
bone density
endocrinologist
osteoanabolic
anti-resorptive
romosuzumab
treatment strategies
×